{"id":"W4306724295","doi":"10.1200/jco.21.02947","title":"Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Novartis Institutes for BioMedical Research; EMD Serono; Genentech; Sierra Oncology; PharmaMar; Astellas Pharma; Eisai; G1 Therapeutics; National Institute of Environmental Health Sciences; MacroGenics; Silverback Therapeutics; INOVIO Pharmaceuticals; Cardinal Health; Puma Biotechnology; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Agios Pharmaceuticals; Ipsen; Array BioPharma; Five Prime Therapeutics; Halozyme; Mirati Therapeutics; Clovis Oncology; Astex Pharmaceuticals; PTC Therapeutics; Sanofi; Exelixis; GlaxoSmithKline; Amgen; Pfizer; Invitae; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Olaparib; Medicine; Prostate cancer; Internal medicine; Hazard ratio; PARP inhibitor; Oncology; Urology; Progression-free survival; Clinical endpoint; Randomized controlled trial; Cancer; Gastroenterology; Overall survival; Poly ADP ribose polymerase; Confidence interval","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002051193,0.001744148,0.003857519,0.0006395903,0.0004171809,0.001441454,0.0009887411,0.002095815,0.006888424],"category_scores_gemma":[0.001997903,0.0007718045,0.002422862,0.0005728255,0.001086821,0.001000773,0.0005830359,0.003236935,0.001019653],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008688681,"about_ca_system_score_gemma":0.001592092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001318544,"about_ca_topic_score_gemma":0.003325216,"domain_scores_codex":[0.9984806,0.001020928,0.00007429211,0.00018284,0.00008672268,0.0001545798],"domain_scores_gemma":[0.9988534,0.0003292557,0.000234753,0.00009876738,0.00007664831,0.0004070316],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9876705,0.002224372,0.0002131904,0.0002630772,0.0007655941,0.00001780762,0.00001137918,0.0002082004,0.000729081,0.0000751995,0.0004311032,0.007390477],"study_design_scores_gemma":[0.9737853,0.02418873,0.0006389495,0.00002203038,0.0004303835,0.00001541031,0.000007914019,0.000245824,0.0001192465,0.000113255,0.000424048,0.000008993984],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9628202,0.01770765,0.001136384,0.002124403,0.00242278,0.005388627,0.002322987,0.0002478254,0.005829077],"genre_scores_gemma":[0.982219,0.003861587,0.001479231,0.00219292,0.0009629527,0.003280356,0.001191399,0.00002744907,0.004785053],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006888424,"threshold_uncertainty_score":0.02304405,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2730445151668799,"score_gpt":0.5330496930102513,"score_spread":0.2600051778433713,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}